Table 1 Baseline characteristics of study patients
| Â | Total | Events | No events | p value |
|---|---|---|---|---|
|  | n = 8417 | n = 395 | n = 8022 |  |
Clinical characteristics | ||||
 Age, years | 57.4 ± 10.8 | 62.2 ± 10.2 | 57.2 ± 10.8 |  < 0.001 |
 Male sex, (%) | 71.7 | 71.6 | 71.7 | 0.993 |
 BMI (kg/m2) | 25.8 ± 3.2 | 25.5 ± 3.2 | 25.9 ± 3.2 | 0.016 |
 Hypertension, (%) | 62.0 | 68.8 | 61.7 | 0.005 |
 Dyslipidemia, (%) | 74.8 | 72.3 | 74.9 | 0.259 |
 Diabetes Mellitus, (%) | 27.5 | 37.1 | 27.0 |  < 0.001 |
 Family history of CAD, (%) | 13.6 | 14.3 | 13.5 | 0.097 |
 Current smoker, (%) | 54.4 | 54.3 | 54.4 | 0.968 |
Laboratory findings | ||||
 TC (mmol/L) | 4.16 ± 1.17 | 4.17 ± 1.26 | 4.15 ± 1.17 | 0.819 |
 LDL-C (mmol/L) | 2.53 ± 1.01 | 2.53 ± 1.11 | 2.53 ± 1.00 | 0.970 |
 HDL-C (mmol/L) | 1.06 ± 0.29 | 1.05 ± 0.29 | 1.06 ± 0.29 | 0.662 |
 TG (mmol/L) | 1.50 (1.10–2.10) | 1.48 (1.06–2.10) | 1.50 (1.10–2.10) | 0.538 |
 Lipoprotein(a) (mg/dL) | 15.18 (6.74–36.79) | 19.24(9.01–45.58) | 15.00 (6.66–36.26) | 0.001 |
 apoA1 (g/L) | 1.33 ± 0.29 | 1.34 ± 0.30 | 1.33 ± 0.29 | 0.726 |
 apoB (g/L) | 0.92 ± 0.30 | 0.93 ± 0.31 | 0.92 ± 0.30 | 0.609 |
 Fibrinogen(g/L) | 3.24 ± 0.79 | 3.35 ± 0.81 | 3.23 ± 0.78 | 0.003 |
 D-dimer (ug/mL) | 0.42 ± 0.62 | 0.55 ± 0.66 | 0.42 ± 0.62 |  < 0.001 |
Medications at admission | ||||
 Statins, (%) | 75.5 | 68.3 | 75.8 | 0.005 |
 Aspirin, (%) | 83.6 | 82.3 | 83.6 | 0.557 |
 ACEI, (%) | 12.5 | 13.3 | 12.5 | 0.682 |
 ARB, (%) | 12.8 | 10.6 | 12.9 | 0.361 |
 β-blockers, (%) | 48.2 | 48.7 | 48.1 | 0.893 |
 CCB, (%) | 19.2 | 15.9 | 19.3 | 0.228 |
Medications at discharge | ||||
 Statins, (%) | 94.0 | 95.5 | 93.9 | 0.313 |
 Aspirin, (%) | 96.2 | 96.9 | 96.2 | 0.638 |
 ACEI, (%) | 22.2 | 26.3 | 22.0 | 0.096 |
 ARB, (%) | 23.0 | 26.3 | 22.9 | 0.175 |
 β-blockers, (%) | 77.9 | 80.6 | 77.8 | 0.278 |
 CCB, (%) | 38.1 | 35.3 | 38.2 | 0.323 |